Pulse Biosciences (PLSE) Stock Forecast & Price Target

Pulse Biosciences is supported by a differentiated nsPFA platform that delivers nanosecond pulses, enabling faster, non-thermal ablation while sparing adjacent tissue, a mechanism that could improve workflow and outcomes versus microsecond PFA and radiofrequency approaches. The company’s fundamentals are strengthened by unusually strong early clinical evidence, including 100% procedural success at six months, 96.2% at 12 months, and roughly 90% freedom from AF/AFL/AT in the European feasibility cohort, alongside rapid NANOPULSE-AF enrollment across 15 sites and 30 physicians. Its outlook is further bolstered by over 250 issued patents, a capital-efficient partnership strategy, and a balance sheet that ended 2Q26 with $101.6M in cash and no debt, supporting development across AF, surgical, and thyroid markets.

Pulse Biosciences is an early-stage, pre-revenue medical device company whose investment case remains highly dependent on unproven clinical outcomes, and any disappointment in NANOPULSE-AF or other pivotal trials could undermine the perceived differentiation of its nsPFA platform. It also faces substantial execution and commercialization risk because its U.S. EP strategy hinges on securing a strategic partner in a market dominated by Abbott, Boston Scientific, Johnson & Johnson Biosense Webster, and Medtronic, while the company reported just $101.6M in cash at the end of the second quarter of 2026 against expected cash burn rising to about $77M in 2026. With limited revenue visibility, forecast losses of ($1.09) adj. LPS in 2026 and ongoing dilution risk from equity financing, the stock remains vulnerable to trial delays, weak investor sentiment, and the burden of funding multiple programs simultaneously.